Clinical Trial Update: Phase I, Study in Chinese NSCLC Patients [Phase 1]

View source ↗

Summary

Phase I trial in Chinese patients with EGFR-mutated non-small cell lung carcinoma completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Carcinoma

Drugs mentioned

• Not specified

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive | Phase 1 | Status: COMPLETED | Results posted: 2017-03-06